罕见的遗传凝血缺陷:一个单中心研究
Özlem Terzi1, Sadik Sami Hatipoğlu2
1Pediatric Hematology and Oncology Clinic.
Journal of pediatric hematology/oncology
|December 23, 2024
概括
罕见因子缺陷 (RFD) 影响100万-1300万个体中的1个. 这项研究强调了基因咨询和及时诊断对于管理RFD儿童危及生命的出血风险的重要性.
科学领域:
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
- 儿科 儿科 儿科
背景情况:
- 罕见因子缺陷 (RFD) 涵盖了一系列影响凝血因子的遗传性出血障碍.
- 这些情况,患病率为1,000,000至3,000,000分之一,可表现为轻度至重度出血症状.
- 综合缺乏,特别是维生素K依赖因素的缺乏,构成了重大的临床挑战.
研究的目的:
- 为现有的关于罕见因子缺陷的文献做出贡献.
- 分析被诊断患有RFD的儿童的特征和结果.
主要方法:
- 对43名被诊断为罕见因子缺乏症的儿科患者的数据进行了回顾性分析.
- 审查医疗记录以确定因素类型,临床表现和管理策略.
主要成果:
- 第七因子缺乏是最常见的 (n=13),其次是第十二因子 (n=9) 和第十因子 (n=6).
- 在43例病例中,有16例涉及血缘结婚,这表明在这种人群中患病率更高.
- 有效的管理策略包括治疗急性出血和预防复发症状.
结论:
- 自体逆向遗传需要改善家族的遗传咨询和诊断.
- 及时诊断和适当的预防措施对于减轻严重,危及生命的出血风险至关重要.
- 了解遗传和环境因素,如血缘关系,对于全面的RFD管理至关重要.
相关概念视频
Disorders of Hemostasis
699
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
699
Anticoagulant Drugs: Low-Molecular-Weight Heparins
608
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
608
Extrinsic and Intrinsic Pathways of Hemostasis
5.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.3K
Coagulation
4.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
4.6K
X-linked Traits
53.4K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
53.4K


